EPS for Corindus Vascular Robotics, Inc. (CVRS) Expected At $-0.05; 25 Bullish Analysts Covering Marvell Technology Group Ltd. (MRVL)

April 17, 2018 - By wolcottdaily

Marvell Technology Group Ltd. (NASDAQ:MRVL) Logo

Analysts expect Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) to report $-0.05 EPS on May, 8.They anticipate $0.02 EPS change or 28.57% from last quarter’s $-0.07 EPS. After having $-0.04 EPS previously, Corindus Vascular Robotics, Inc.’s analysts see 25.00% EPS growth. The stock increased 0.85% or $0.01 during the last trading session, reaching $1.19. About 400,052 shares traded. Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) has risen 23.68% since April 17, 2017 and is uptrending. It has outperformed by 12.13% the S&P500.

Among 38 analysts covering Marvell Technology Group (NASDAQ:MRVL), 25 have Buy rating, 1 Sell and 12 Hold. Therefore 66% are positive. Marvell Technology Group had 126 analyst reports since August 5, 2015 according to SRatingsIntel. Susquehanna upgraded Marvell Technology Group Ltd. (NASDAQ:MRVL) on Friday, November 18 to “Positive” rating. Jefferies maintained Marvell Technology Group Ltd. (NASDAQ:MRVL) rating on Friday, March 9. Jefferies has “Buy” rating and $29.0 target. The stock of Marvell Technology Group Ltd. (NASDAQ:MRVL) has “Buy” rating given on Monday, November 20 by FBR Capital. The firm earned “Neutral” rating on Monday, September 14 by UBS. The company was maintained on Monday, September 14 by Cowen & Co. The rating was maintained by Piper Jaffray with “Buy” on Thursday, March 8. The stock of Marvell Technology Group Ltd. (NASDAQ:MRVL) earned “Buy” rating by KeyBanc Capital Markets on Monday, March 19. Cowen & Co maintained the shares of MRVL in report on Tuesday, September 6 with “Outperform” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, September 14. On Wednesday, August 19 the stock rating was upgraded by Ladenburg Thalmann to “Buy”. See Marvell Technology Group Ltd. (NASDAQ:MRVL) latest ratings:

05/04/2018 Broker: UBS Rating: Buy New Target: $38 Initiates Coverage On
19/03/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $29.0 Maintain
09/03/2018 Broker: Jefferies Rating: Buy New Target: $29.0 Maintain
09/03/2018 Broker: Cowen & Co Rating: Buy New Target: $29.0 Maintain
09/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $22 New Target: $23 Maintain
09/03/2018 Broker: Oppenheimer Rating: Buy New Target: $30.0 Maintain
08/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $28.0 Maintain
08/03/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $21.0 Maintain
07/03/2018 Broker: Susquehanna Rating: Buy New Target: $29.0 Maintain
07/03/2018 Broker: Argus Research Rating: Buy New Target: $28 Initiates Coverage On

Marvell Technology Group Ltd. designs, develops, and markets analog, mixed-signal, digital signal processing, and embedded and standalone integrated circuits. The company has market cap of $10.96 billion. It offers a range of storage products, such as hard disk drive and solid-state drive controllers, as well as HDD components, such as HDD preamps components; and develops software enabled silicon solutions consisting of serial advanced technology attachment port multipliers, bridges, serial attached SCSI, and non-volatile memory express redundant array of independent disks controllers and converged storage processors for enterprise, data centers, and cloud computing businesses. It has a 21.59 P/E ratio. The firm also provides networking products comprising Ethernet solutions comprising Ethernet switches, Ethernet physical-layer transceivers, and single-chip network interface devices; and embedded communication processors.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.15, from 1.1 in 2017Q3. It improved, as 28 investors sold Marvell Technology Group Ltd. shares while 99 reduced holdings. 56 funds opened positions while 103 raised stakes. 434.31 million shares or 15.21% more from 376.98 million shares in 2017Q3 were reported. Janney Montgomery Scott Limited Liability invested in 0.01% or 33,501 shares. Brahman Capital Corp, a New York-based fund reported 3.44 million shares. Arrowgrass Capital Prtnrs (Us) Limited Partnership reported 0.27% of its portfolio in Marvell Technology Group Ltd. (NASDAQ:MRVL). Invesco Ltd invested 0.01% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Baystate Wealth Ltd Liability Com owns 70 shares for 0% of their portfolio. The Massachusetts-based State Street has invested 0.02% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Advisory Service Network Limited Company stated it has 0.01% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Baker Avenue Asset Mgmt Limited Partnership stated it has 39,323 shares or 0.08% of all its holdings. Canada Pension Plan Invest Board holds 0.09% in Marvell Technology Group Ltd. (NASDAQ:MRVL) or 2.20 million shares. Amer International Grp Inc Inc has invested 0% in Marvell Technology Group Ltd. (NASDAQ:MRVL). 2,065 were accumulated by Assetmark. Cohen Klingenstein reported 19,190 shares stake. Svcs Automobile Association invested 0.03% in Marvell Technology Group Ltd. (NASDAQ:MRVL). Shannon River Fund Ltd Liability Corporation holds 4.89% of its portfolio in Marvell Technology Group Ltd. (NASDAQ:MRVL) for 949,010 shares. Whittier has invested 0% of its portfolio in Marvell Technology Group Ltd. (NASDAQ:MRVL).

The stock increased 1.40% or $0.305 during the last trading session, reaching $22.065. About 2.21M shares traded. Marvell Technology Group Ltd. (NASDAQ:MRVL) has risen 35.98% since April 17, 2017 and is uptrending. It has outperformed by 24.43% the S&P500.

Corindus Vascular Robotics, Inc. designs, makes, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures. The company has market cap of $224.64 million. The firm offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. It currently has negative earnings. The Company’s CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise, robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit.

Marvell Technology Group Ltd. (NASDAQ:MRVL) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>